Highlights

• think if we want to use it [Corlanor] more often then of course we need to have more data, and better data to convince us, and the problem is also that the patient receives so many medications that the compliance of the patient to take on this medication for years is so bad that you reduce your medications to what is really needed, and what is really proven by data, and this is beta blockers, ACE inhibitors and spironolactone, and an aldosterone antagonist. Those are the most important drugs, and if you add and add and add, then the patient will not take his medications, and then you are completely lost. 
• Sometimes it [Entresto] is too effective, and I see a lot of patients with hypotension, and also kidney problems, with a rise in creatinine levels, and so I have to stop the medication. So, that is a limitation for me. Another problem is the increase in the titration of the dosage of Entresto, it is very difficult and people are not used to it, so many patients stay on the very low dosage of Entresto because the general practitioner does not dare to increase the dose because he is afraid of hypotension, and then the patients stay on a notso-effective dose of Entresto.
• We have a federal institute that evaluates the therapies, and for Entresto this therapy has been evaluated, and an additional advantage has been attested for Entresto, so it has been officially evaluated, and they say it is better than an ACEi, and I think that is much more important for translation into clinical practice than the guidelines.